VolitionRx's Finger-Prick Test Shows Promise in Sepsis Detection
Event summary
- VolitionRx's lateral flow prototype test correlated strongly with its established Nu.Q® NETs assay in sepsis patients, with Spearman and Pearson correlations of 0.85 and 0.88 respectively.
- The finger-prick test could enable rapid, decentralized testing in ERs or at the bedside, expanding beyond centralized lab testing.
- VolitionRx targets the $3.8 billion global addressable market for NETosis testing, with potential applications in low-income countries lacking lab infrastructure.
The big picture
VolitionRx's breakthrough in sepsis detection aligns with broader trends toward decentralized, point-of-care diagnostics. The $3.8 billion global addressable market for NETosis testing represents a significant opportunity, particularly in regions where centralized lab infrastructure is limited. The company's ability to leverage this technology could reshape early disease detection and monitoring strategies.
What we're watching
- Market Expansion
- Whether VolitionRx can successfully penetrate low-income countries with weak lab infrastructure through NGO partnerships and strategic collaborations.
- Regulatory Approval
- The pace at which VolitionRx advances its lateral flow prototype from prototype to commercialization, including necessary regulatory clearances.
- Competitive Positioning
- How VolitionRx's decentralized testing solution differentiates it in the highly competitive diagnostics market.
Related topics